Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

被引：0
作者：
Phan, A. T. [1 ]
Wolin, E. M. [2 ]
Fisher, G. A. [3 ]
Ruszniewski, P. [4 ]
Pavel, M. [5 ]
Liyanage, N. [6 ]
Mirakhur, B. [7 ]
Braun, S. [6 ]
Caplin, M. [8 ]
Vinik, A., I [9 ]
机构：
[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Beaujon Hosp, Clichy, France
[5] Charite Univ Med Berlin, Berlin, Germany
[6] Ipsen, Les Ulis, France
[7] Ipsen, Basking Ridge, NJ USA
[8] Royal Free Hosp, London, England
[9] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
lanreotide; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K17
引用
收藏
页码：206 / 206
页数：1
相关论文
共 35 条
  • [31] Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
    Giovannoni, Gavin
    Kappos, Ludwig
    Gold, Ralf
    Khatri, Bhupendra O.
    Selmaj, Krzysztof
    Umans, Kimberly
    Greenberg, Steven J.
    Sweetser, Marianne
    Elkins, Jacob
    McCroskery, Peter
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 9 : 36 - 46
  • [32] Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies
    Campbell Howard
    Adele Noe
    Andrej Skerjanec
    Björn Holzhauer
    Margaret Wernsing
    Monica Ligueros-Saylan
    Tom Thuren
    Cardiovascular Diabetology, 13
  • [33] Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies
    Howard, Campbell
    Noe, Adele
    Skerjanec, Andrej
    Holzhauer, Bjoern
    Wernsing, Margaret
    Ligueros-Saylan, Monica
    Thuren, Tom
    CARDIOVASCULAR DIABETOLOGY, 2014, 13
  • [34] Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials
    Wilson, Jacquelyn G.
    Bass, Almasa
    Pixton, Glenn C.
    Wolfram, Gernot
    Rauck, Richard L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (01) : 91 - 99
  • [35] Safety and Tolerability of Once-Daily OROS® Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer Pain: Pooled Analysis of 11 Clinical Studies
    Nalamachu, Srinivas R.
    Kutch, Michael
    Hale, Martin E.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2012, 44 (06) : 852 - 865
1234